Evidence map›Paper›PMID 34208188›Full record

ArticleJournal of personalized medicine2021

Feasibility and Assessment of a Cascade Traceback Screening Program (FACTS): Protocol for a Multisite Study to Implement and Assess an Ovarian Cancer Traceback Cascade Testing Program.

Anna DiNucci, Nora B Henrikson, M Cabell Jonas, Sundeep Basra, Paula Blasi, Jennifer Brown, Edward D Esplin, Dina Hassen, Jing Hao, Yirui Hu and 16 more

Abstract read
In one paragraph

Article in Journal of personalized medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

26 authors.

Anna DiNucciMid-Atlantic Permanente Research Institute, 2101 E. Jefferson St, Rockville, MD 20852, USA.
Nora B HenriksonKaiser Permanente Washington Health Research Institute, 1730 Minor Ave, Seattle, WA 98101, USA.ORCID 0000-0002-3459-7787
M Cabell JonasMid-Atlantic Permanente Research Institute, 2101 E. Jefferson St, Rockville, MD 20852, USA.
Sundeep BasraMid-Atlantic Permanente Research Institute, 2101 E. Jefferson St, Rockville, MD 20852, USA.ORCID 0000-0003-0040-9896
Paula BlasiKaiser Permanente Washington Health Research Institute, 1730 Minor Ave, Seattle, WA 98101, USA.
Jennifer BrownMid-Atlantic Permanente Research Institute, 2101 E. Jefferson St, Rockville, MD 20852, USA.
Edward D EsplinInvitae Corporation, 1400 16th St, San Francisco, CA 94103, USA.ORCID 0000-0001-9205-3756
Dina HassenGeisinger Department of Population Health Sciences, 100 N. Academy Ave, Danville, PA 17822, USA.
Jing HaoGeisinger Department of Epidemiology and Health Services Research, 100 N. Academy Ave, Danville, PA 17822, USA.
Yirui HuGeisinger Department of Population Health Sciences, 100 N. Academy Ave, Danville, PA 17822, USA.
Tracey KlingerGeisinger Genomic Medicine Institute, 100 N. Academy Ave, Danville, PA 17822, USA.
Ilene LaddGeisinger Genomic Medicine Institute, 100 N. Academy Ave, Danville, PA 17822, USA.
Kathleen LeppigKaiser Permanente Washington Health Research Institute, 1730 Minor Ave, Seattle, WA 98101, USA.
Meredith LewisGeisinger Genomic Medicine Institute, 100 N. Academy Ave, Danville, PA 17822, USA.
Michelle MeyerGeisinger, Center for Translational Bioethics & Health Care Policy, 100 N. Academy Ave, Danville, PA 17822, USA.
Steven NeyGeisinger Genomic Medicine Institute, 100 N. Academy Ave, Danville, PA 17822, USA.
Arvind RamaprasanKaiser Permanente Washington Health Research Institute, 1730 Minor Ave, Seattle, WA 98101, USA.
Katrina RomagnoliGeisinger Genomic Medicine Institute, 100 N. Academy Ave, Danville, PA 17822, USA.
Zachary SalvatiGeisinger Genomic Medicine Institute, 100 N. Academy Ave, Danville, PA 17822, USA.
Aaron ScrolKaiser Permanente Washington Health Research Institute, 1730 Minor Ave, Seattle, WA 98101, USA.
Rachel SchwiterGeisinger Genomic Medicine Institute, 100 N. Academy Ave, Danville, PA 17822, USA.
Leigh SheridanKaiser Permanente Washington Health Research Institute, 1730 Minor Ave, Seattle, WA 98101, USA.
Brinda SomasundaramMid-Atlantic Permanente Research Institute, 2101 E. Jefferson St, Rockville, MD 20852, USA.
Pim SuwannaratMid-Atlantic Permanente Research Institute, 2101 E. Jefferson St, Rockville, MD 20852, USA.
Jennifer K WagnerGeisinger, Center for Translational Bioethics & Health Care Policy, 100 N. Academy Ave, Danville, PA 17822, USA.
Alanna K RahmGeisinger Genomic Medicine Institute, 100 N. Academy Ave, Danville, PA 17822, USA.

Funding

Feasibility and Assessment of a Cascade Traceback Screening program - FACTSU01CA240747 · NCI · GEISINGER CLINIC · PI BUCHANAN, ADAM H, HENRIKSON, NORA B. · 2020 to 2023
$2.9M
NCI NIH HHS U01 CA240747NIH HHS U01 CA240747-01A1
6 · The paper itself

Abstract

Ovarian cancer (OVCA) patients may carry genes conferring cancer risk to biological family; however, fewer than one-quarter of patients receive genetic testing. "Traceback" cascade testing -outreach to potential probands and relatives-is a possible solution. This paper outlines a funded study (U01 CA240747-01A1) seeking to determine a Traceback program's feasibility, acceptability, effectiveness, and costs. This is a multisite prospective observational feasibility study across three integrated health systems. Informed by the Conceptual Model for Implementation Research, we will outline, implement, and evaluate the outcomes of an OVCA Traceback program. We will use standard legal research methodology to review genetic privacy statutes; engage key stakeholders in qualitative interviews to design communication strategies; employ descriptive statistics and regression analyses to evaluate the site differences in genetic testing and the OVCA Traceback testing; and assess program outcomes at the proband, family member, provider, system, and population levels. This study aims to determine a Traceback program's feasibility and acceptability in a real-world context. It will account for the myriad factors affecting implementation, including legal issues, organizational- and individual-level barriers and facilitators, communication issues, and program costs. Project results will inform how health care providers and systems can develop effective, practical, and sustainable Traceback programs.

Indexed as

genetic testingHIPAAimplementationimplementation researchmicro-costingovarian cancertraceback cascade testing program

Identifiers

PMID34208188
PMCPMC8230764

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.